The BRSK2 Knockout HeLa Polyclonal Cells consist of a population of HeLa cells edited via CRISPR/Cas9-mediated disruption of the BRSK2 gene. This polyclonal knockout model provides a heterogeneous pool of gene-edited cells, enabling BRSK2 loss-of-function studies in a widely used human cancer cell background. The polyclonal format retains genetic diversity while achieving targeted disruption, facilitating robust functional assays and minimizing clonal artifacts. The edited population serves as a versatile tool for investigating BRSK2-dependent signaling networks and cell cycle regulation.
The parental HeLa cell line is a human cervical epithelial adenocarcinoma model, positive for human papillomavirus type 18 (HPV18) and characterized by inactivation of p53 via HPV E6 oncoprotein expression. This immortalized cell line is extensively employed in cancer biology, virology, and signal transduction research due to its robust growth and well-characterized molecular alterations. The HeLa background offers a relevant context for studying oncogenic signaling and cell cycle dysregulation, making it suitable for knockout models targeting kinases involved in checkpoint control.
BRSK2 (BR serine/threonine kinase 2) is an AMPK-related kinase activated by the LKB1-STRADA-CAB39/MO25 complex. It phosphorylates WEE1, CDC25B, and CDC25C, leading to inhibitory phosphorylation of CDK1 and G2/M arrest. BRSK2 also participates in neuronal polarization and mTORC1 signaling, functioning downstream of LKB1. Interaction partners include 14-3-3 proteins, which modulate its localization and activity. In HeLa cells, BRSK2 knockout dysregulates the LKB1-BRSK2-WEE1/CDC25 axis, offering a tractable system for dissecting these phosphorylation cascades.
In HeLa cells, where p53 is functionally absent, cell cycle checkpoints rely partly on the LKB1-BRSK2 pathway. Disruption of BRSK2 abrogates a critical G2/M restraint, potentially enhancing proliferation and altering sensitivity to genotoxic agents. This model is valuable for exploring checkpoint adaptation in p53-deficient tumors, such as cervical cancer and glioblastoma. BRSK2 loss-of-function mutations are also linked to intellectual disability and autism spectrum disorder, extending the model??s relevance to neurodevelopmental research.
These polyclonal BRSK2 knockout HeLa cells enable various experimental approaches. Flow cytometry using propidium iodide or BrdU staining permits cell cycle analysis, while Western blotting for phospho-WEE1 (Ser642) and CDK1 (Tyr15) assesses BRSK2 signaling. Colony formation and apoptosis assays evaluate proliferation and drug responses, particularly to kinase inhibitors targeting LKB1 or mTORC1 pathways. RT-qPCR for BRSK2 target genes complements protein studies. These cells also support CRISPR-based modifier screens and chemical probe validation. For further information, contact Ascent Research.
